TranS1 defends US antitrust claims against Blue Cross
( August 25, 2025, 22:31 GMT | Official Statement) -- MLex Summary: TranS1 opposed a motion to dismiss US antitrust claims accusing Blue Cross Blue Shield of conspiring to keep it out of the market for spinal fusions. “The Third Circuit in Lifewatch reversed the dismissal of antitrust claims nearly identical to plaintiff TranS1’s claims here. The Lifewatch plaintiff alleged that ‘the Blue Plans have impermissibly conspired with each other and the Association to deny coverage of telemetry monitors,’ a medical device the plaintiff sold,” it argued. See attached file. ...
Prepare for tomorrow’s regulatory change, today
MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.
Know what others in the room don’t, with features including:
- Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
- Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
- Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
- Curated case files bringing together news, analysis and source documents in a single timeline
Experience MLex today with a 14-day free trial.